Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like Medtronic Receives CE Mark For Its Next Generation Cardiac Resynchronization Therapy-Pacemakers February 23, 2017 Big Names in Biotech Seek $1M to Build Life-Size Statue of Legend Henri Termeer January 24, 2018 Bay Area's DNAnexus Scores $58M to Accelerate Expansion January 1, 2018
Medtronic Receives CE Mark For Its Next Generation Cardiac Resynchronization Therapy-Pacemakers February 23, 2017
